Merck Serono Expands Cilengitide Development Program
Cilengitide clinical development program now aimed at three cancer types
18-Mar-2009 -
Merck Serono announced the launch of its Phase II clinical study CERTOa, which will investigate the efficacy and safety of the novel combination of the investigational integrin inhibitor, cilengitide, and Erbitux® (cetuximab), with cisplatin and either vinorelbine or gemcitabine, as 1st-line ...
angiogenesis
chemotherapy
cisplatin
+9